The report "Clinical Chemistry Analyzers Market by Product (Fully-Automated Analyzers, PoC Analyzers, Reagents), Test Type (Basic Metabolic, Liver, Renal, Lipid, Thyroid Function), End User (Hospitals, Clinics, Laboratories, Research) – Global Forecast to 2026"The global clinical chemistry analyzers market size is projected to reach USD 15.2 billion by 2026 from USD 12.3 billion in 2021, at a 4.3% CAGR.The rising geriatric population and the increasing prevalence of chronic & lifestyle diseases, growing adoption of Point-of-Care testing devices and rising demand for laboratory automation drives growth in the clinical chemistry analyzers market. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the clinical chemistry analyzers market.
Browse 104 market data Tables and 36 Figures spread through 163 Pages and in-depth TOC on "Clinical Chemistry Analyzers Market by Product (Fully-Automated Analyzers, PoC Analyzers, Reagents), Test Type (Basic Metabolic, Liver, Renal, Lipid, Thyroid Function), End User (Hospitals, Clinics, Laboratories, Research) – Global Forecast to 2026"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/clinical-chemistry-analyzer-market-144027310.html
The reagents segment accounted for the largest share of the clinical chemistry analyzers market, by product segment, in 2020
Based on product, the clinical chemistry analyzers market is segmented into reagents, analyzers and other products. The reagents segment accounted for the largest share of the clinical chemistry analyzers market in 2020. The recurrent requirement of reagents in large numbers compared to analyzers is the major factor driving this segments growth.
Lipid profile tests segment to register the highest growth rate during the forecast period
The clinical chemistry analyzers market is segmented basic metabolic panels, electrolyte panels, liver panels, lipid profiles, renal profiles, thyroid function panels, and specialty chemical tests. based on test type. In 2020, the lipid profile tests segment accounted for the highest growth rate. This can be attributed to the Rapid growth in obesity rates and the increasing incidence of obesity-related diseases
The hospitals and clinics segment accounted for the largest share of the clinical chemistry analyzers market, by end user segment, in 2020
Based on end-users, the clinical chemistry analyzers market is segmented into hospitals and clinics, diagnostic laboratories, research laboratories & institutes, and other end users. In 2020, hospitals and clinics accounted for the largest share of the clinical chemistry analyzers market. The increasing number of hospitals worldwide owing to the increasing incidences of diseases & disorders, increasing adoption of analyzers and rising technological advancements are the major factors driving this segments growth.
North America is the largest regional market for clinical chemistry analyzers market
The clinical chemistry analyzers market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the clinical chemistry analyzers market. The large share of this region can be attributed to the the increasing geriatric population, increasing prevalence of chronic & lifestyle conditions, implementation of favorable government initiatives, increasing healthcare expenditure, improved healthcare infrastructure, and the availability of technologically advanced instruments.
The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China), and AMS Alliance (Italy).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441